These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 7864298)

  • 21. DNA level, tumor thickness, and stereological estimates of nuclear volume in stage I cutaneous malignant melanomas. A comparative study with analysis of prognostic impact.
    Sørensen FB; Kristensen IB; Grymer F; Jakobsen A
    Am J Dermatopathol; 1991 Feb; 13(1):11-9. PubMed ID: 2003643
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Xeroderma pigmentosum. Complementation group C and malignant melanoma.
    Lynch HT; Fusaro RM; Johnson JA
    Arch Dermatol; 1984 Feb; 120(2):175-9. PubMed ID: 6696469
    [No Abstract]   [Full Text] [Related]  

  • 23. Primary cutaneous myxoid melanoma: immunohistologic clues to a difficult diagnosis.
    Prieto VG; Kanik A; Salob S; McNutt NS
    J Am Acad Dermatol; 1994 Feb; 30(2 Pt 2):335-9. PubMed ID: 8294593
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Regression of melanoma metastases and multiple non-melanoma skin cancers in xeroderma pigmentosum by the PD1-antibody pembrolizumab.
    Hauschild A; Eichstaedt J; Möbus L; Kähler K; Weichenthal M; Schwarz T; Weidinger S
    Eur J Cancer; 2017 May; 77():84-87. PubMed ID: 28365530
    [No Abstract]   [Full Text] [Related]  

  • 25. Conjunctival malignant melanoma with xeroderma pigmentosum.
    Aoyagi M; Morishima N; Yoshino Y; Imagawa N; Kiyosawa M; Ito M; Kondou S; Matsubara O
    Ophthalmologica; 1993; 206(3):162-7. PubMed ID: 8272340
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Morphometric, DNA and PCNA in thin malignant melanomas.
    Björnhagen V; Månsson-Brahme E; Lindholm J; Mattsson A; Auer G
    Med Oncol Tumor Pharmacother; 1993; 10(3):87-94. PubMed ID: 7903405
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immunohistochemical expression of p53 protein, mitotic index and nuclear morphometry in primary malignant melanoma of the skin.
    Talve L; Kainu J; Collan Y; Ekfors T
    Pathol Res Pract; 1996 Aug; 192(8):825-33. PubMed ID: 8897518
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Nuclear pseudoinclusions in melanocytic naevi and melanomas.
    Rose DS
    J Clin Pathol; 1995 Jul; 48(7):676-7. PubMed ID: 7560180
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long-term survival and preservation of natural killer cell activity in a xeroderma pigmentosum patient with spontaneous regression and multiple deposits of malignant melanoma.
    Anstey AV; Arlett CF; Cole J; Norris PG; Hamblin AS; Limb GA; Lehmann AR; Wilkinson JD; Turner M
    Br J Dermatol; 1991 Sep; 125(3):272-8. PubMed ID: 1911321
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Malignant schwannoma associated with xeroderma pigmentosum in a patient belonging to complementation group D.
    Nakamura T; Ono T; Yoshimura K; Arao T; Kondo S; Ichihashi M; Matsumoto A; Fujiwara Y
    J Am Acad Dermatol; 1991 Aug; 25(2 Pt 2):349-53. PubMed ID: 1894771
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical and genetic characteristics of xeroderma pigmentosum in Nepal.
    Espi P; Parajuli S; Benfodda M; Lebre AS; Paudel U; Grange A; Grybek V; Grange T; Soufir N; Grange F
    J Eur Acad Dermatol Venereol; 2018 May; 32(5):832-839. PubMed ID: 29178624
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Collision of squamous-cell carcinoma with melanoma in situ in a child with xeroderma pigmentosum.
    Hofer A; Kaddu S; Seidl H; Kerl H; Wolf P
    Dermatology; 2001; 203(1):66-9. PubMed ID: 11549805
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Xeroderma pigmentosum with multiple malignancies.
    Nalgirkar AR; Borkar SS; Nalgirkar SA
    Indian Pediatr; 2000 Dec; 37(12):1377-9. PubMed ID: 11119344
    [No Abstract]   [Full Text] [Related]  

  • 34. Xeroderma pigmentosum in Qatar.
    Fathy S; Khafagy H
    Cutis; 1986 May; 37(5):377-9. PubMed ID: 3709228
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Discrimination between benign and malignant melanocytic skin lesions by multivariate analysis, quantitative S-100 immunohistochemistry, nuclear morphometry and DNA cytometry.
    Williams RA; Rode J; Baak JP; Charlton IG
    Anal Quant Cytol Histol; 1999 Aug; 21(4):353-7. PubMed ID: 10560514
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Superficial spreading melanoma and blue naevus within naevus spilus--ultrastructural assessment of giant pigment granules.
    Cox NH; Malcolm A; Long ED
    Dermatology; 1997; 194(3):213-6. PubMed ID: 9187835
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Xeroderma pigmentosum complementation group G in association with malignant melanoma.
    Yoneda K; Moriue J; Matsuoka Y; Moriwaki S; Moriue T; Nakai K; Yokoi I; Nibu N; Demitsu T; Kubota Y
    Eur J Dermatol; 2007; 17(6):540-1. PubMed ID: 17951140
    [No Abstract]   [Full Text] [Related]  

  • 38. Stereological estimation of nuclear volume in benign melanocytic lesions and cutaneous malignant melanomas.
    Sørensen FB
    Am J Dermatopathol; 1989 Dec; 11(6):517-27. PubMed ID: 2604019
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Significance of long-term follow-up in xeroderma pigmentosum.
    Min JA; Lee JY; Cho BK; Park HJ
    Int J Dermatol; 2010 Jun; 49(6):720-2. PubMed ID: 20618485
    [No Abstract]   [Full Text] [Related]  

  • 40. [XERODERMA PIGMENTOSUM. 8 CASES OF DIFFERENT EVOLUTION IN 2 FAMILIES].
    LEMAIRE M; GAUMOND E
    Can Med Assoc J; 1965 Feb; 92(8):406-12. PubMed ID: 14261153
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.